RS is an independent measure for BCSS and recurrence prognoses relative to OS in early-stage breast cancer. It carries more prognostic information for breast cancer-specific outcomes.
Keyphrases
- genome wide analysis
- phase iii
- clinical trial
- early stage
- double blind
- open label
- phase ii
- free survival
- placebo controlled
- squamous cell carcinoma
- healthcare
- radiation therapy
- gene expression
- randomized controlled trial
- breast cancer risk
- cross sectional
- genome wide
- copy number
- lymph node
- metabolic syndrome
- young adults
- transcription factor